文献速递垂体与肾上腺疾病

双胍类药物通过AMPK依赖和非依赖机制在垂体瘤细胞中发挥抗肿瘤作用

Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该研究探讨双胍类(二甲双胍、丁福明、苯乙双胍)对垂体神经内分泌肿瘤(PitNETs)原代细胞和细胞系的直接作用。结果显示双胍类降低所有PitNETs和细胞系的细胞活力(苯乙双胍最有效),并在生长激素瘤中增加凋亡;丁福明和苯乙双胍(而非二甲双胍)以细胞类型特异性方式减少激素分泌;二甲双胍联合生长抑素类似物(SSAs)未增强SSA单药疗效。

要点

  • 双胍类降低PitNETs细胞活力,苯乙双胍作用最强。
  • 丁福明和苯乙双胍减少激素分泌,二甲双胍无此作用。
  • 二甲双胍联合SSA未优于SSA单药。

核心结论

  • 双胍类对PitNET细胞具有明确的抗肿瘤作用,机制涉及AMPK依赖和非依赖途径。

研究设计与样本

  • 使用13例促肾上腺皮质激素瘤、13例生长激素瘤、13例无功能PitNETs、3例催乳素瘤及2种垂体瘤细胞系(AtT-20和GH3)评估双胍类的直接效应。

主要发现

  • 双胍类降低所有PitNETs和细胞系的细胞活力,苯乙双胍最有效。
  • 双胍类在生长激素瘤中增加凋亡。
  • 丁福明和苯乙双胍(而非二甲双胍)以细胞类型特异性方式减少激素分泌。
  • 二甲双胍联合SSA治疗未增加SSA单药疗效。
  • 双胍类作用可能涉及调控AMPK依赖([Ca2+]i、PI3K/Akt)和非依赖(MAPK)机制。

临床怎么用

  • 双胍类(尤其苯乙双胍)可能成为PitNETs的潜在治疗药物,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pituitary neuroendocrine tumors (PitNETs) are a commonly underestimated pathology in terms of incidence and associated morbimortality. Currently, an appreciable subset of patients are resistant or poorly responsive to the main current medical treatments [i.e., synthetic somatostatin analogs (SSAs) and dopamine agonists]. Thus, development and optimization of novel and available medical therapies is necessary. Biguanides (metformin, buformin, and phenformin) are antidiabetic drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on PitNETs are poorly known. OBJECTIVE: We aimed to explore the direct effects of biguanides on key functions (cell viability, hormone release, apoptosis, and signaling pathways) in primary cell cultures from human PitNETs and cell lines. Additionally, we evaluated the effect of combined metformin with SSAs on cell viability and hormone secretion. DESIGN: A total of 13 corticotropinomas, 13 somatotropinomas, 13 nonfunctioning PitNETs, 3 prolactinomas, and 2 tumoral pituitary cell lines (AtT-20 and GH3) were used to evaluate the direct effects of biguanides on cell viability, hormone release, apoptosis, and signaling pathways. RESULTS: Biguanides reduced cell viability in all PitNETs and cell lines (with phenformin being the most effective biguanide) and increased apoptosis in somatotropinomas. Moreover, buformin and phenformin, but not metformin, reduced hormone secretion in a cell type-specific manner. Combination metformin/SSA therapy did not increase SSA monotherapy effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMP-activated protein kinase-dependent ([Ca2+]i, PI3K/Akt) and independent (MAPK) mechanisms. CONCLUSION: Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells, opening avenues to explore their potential as drugs to treat these pathologies.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, et al. Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms. J Clin Endocrinol Metab. 2019. PMID: 30860580. doi:10.1210/jc.2019-00056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。